CN1098254C - 新的磺酰胺 - Google Patents

新的磺酰胺 Download PDF

Info

Publication number
CN1098254C
CN1098254C CN95196948A CN95196948A CN1098254C CN 1098254 C CN1098254 C CN 1098254C CN 95196948 A CN95196948 A CN 95196948A CN 95196948 A CN95196948 A CN 95196948A CN 1098254 C CN1098254 C CN 1098254C
Authority
CN
China
Prior art keywords
methoxyphenoxy
pyrimidin
pyridin
hydroxyethoxy
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN95196948A
Other languages
English (en)
Chinese (zh)
Other versions
CN1170407A (zh
Inventor
V·布鲁
K·伯里
J－M·卡瑟尔
M·克罗泽尔
G·海尔斯
B·M·罗夫尔
M·穆勒
W·内哈特
H·拉穆兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1170407A publication Critical patent/CN1170407A/zh
Application granted granted Critical
Publication of CN1098254C publication Critical patent/CN1098254C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bipolar Transistors (AREA)
  • Surgical Instruments (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Lubricants (AREA)
CN95196948A 1994-12-20 1995-12-08 新的磺酰胺 Expired - Lifetime CN1098254C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH3837/94-6 1994-12-20
CH3837/946 1994-12-20
CH383794 1994-12-20
CH2419/95-1 1995-08-24
CH241995 1995-08-24
CH2419/951 1995-08-24

Publications (2)

Publication Number Publication Date
CN1170407A CN1170407A (zh) 1998-01-14
CN1098254C true CN1098254C (zh) 2003-01-08

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95196948A Expired - Lifetime CN1098254C (zh) 1994-12-20 1995-12-08 新的磺酰胺

Country Status (25)

Country Link
US (1) US6004965A (enExample)
EP (1) EP0799209B1 (enExample)
JP (1) JP2989014B2 (enExample)
KR (1) KR100445085B1 (enExample)
CN (1) CN1098254C (enExample)
AT (1) ATE246681T1 (enExample)
AU (1) AU701767B2 (enExample)
BR (1) BR9510104A (enExample)
CA (1) CA2208018C (enExample)
CY (1) CY2495B1 (enExample)
CZ (1) CZ287916B6 (enExample)
DE (1) DE69531457T2 (enExample)
DK (1) DK0799209T3 (enExample)
ES (1) ES2203649T3 (enExample)
FI (1) FI120397B (enExample)
HU (1) HU228619B1 (enExample)
IL (1) IL116385A (enExample)
MA (1) MA23744A1 (enExample)
MY (1) MY131126A (enExample)
NO (1) NO316645B1 (enExample)
NZ (1) NZ297797A (enExample)
PT (1) PT799209E (enExample)
SA (1) SA95160421B1 (enExample)
TW (1) TW313568B (enExample)
WO (1) WO1996019459A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2615357T3 (es) 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
ATE267808T1 (de) * 1997-08-19 2004-06-15 Hoffmann La Roche Verfahren zur herstellung von 2,5- disubstituierten pyridinen
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
EP0979822B1 (en) * 1998-08-10 2005-11-30 F. Hoffmann-La Roche Ag Process for the preparation of 2-carbamoyl-pyridines
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
ES2295048T3 (es) 1999-09-03 2008-04-16 Actelion Pharmaceuticals Ltd. Bis-sulfonamidas.
IL149529A0 (en) * 1999-12-22 2002-11-10 Actelion Pharmaceuticals Ltd Butyne diol derivatives
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2002053557A1 (en) * 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
AU2003285321B2 (en) 2002-12-02 2010-04-08 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
NZ586285A (en) 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2008009435A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
CA2672049C (en) 2006-12-08 2016-05-10 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
DK2207775T3 (da) 2007-11-05 2012-06-18 Novartis Ag 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose
JP5421282B2 (ja) 2007-12-03 2014-02-19 ノバルティス アーゲー 高脂血症または動脈硬化症のような疾患の処置に有用なｃｅｔｐ阻害剤としての１，２−二置換−４−ベンジルアミノ−ピロリジン誘導体
SG175925A1 (en) 2009-05-15 2011-12-29 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
AU2010247391A1 (en) 2009-05-15 2011-12-01 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
BRPI1011657A2 (pt) 2009-05-28 2019-04-16 Novartis Ag derivados aminopropiônicos substituídos como inibidores de neprilisina
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
WO2011061168A1 (en) 2009-11-17 2011-05-26 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
CA2796068C (en) 2010-04-15 2022-07-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
SG11201600211XA (en) 2013-07-25 2016-02-26 Novartis Ag Cyclic polypeptides for the treatment of heart failure
TW201518323A (zh) 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑
JP2023548185A (ja) * 2020-11-05 2023-11-15 イドーシア ファーマシューティカルズ リミテッド クラゾセンタン二ナトリウム塩の安定な結晶性水和物
TW202329952A (zh) 2021-12-17 2023-08-01 瑞士商愛杜西亞製藥有限公司 克拉生坦(clazosentan)二鈉鹽之製備方法
WO2025151724A1 (en) * 2024-01-12 2025-07-17 Rectify Pharmaceuticals, Inc. Pyridinyloxypyridines as modulators of atp -binding cassette transporters and their use in treating medical conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510526A1 (de) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide
EP0526708A1 (de) * 1991-06-13 1993-02-10 F. Hoffmann-La Roche Ag Sulfonamide, ihre Herstellung und Verwendung als Heilmittel und Zwischenprodukte
EP0633259A1 (de) * 1993-06-28 1995-01-11 F. Hoffmann-La Roche Ag Neue Sulfonylaminopyrimidine, ihre Herstellung und Verwendung als Heilmittel
EP0658548A1 (en) * 1993-12-17 1995-06-21 Tanabe Seiyaku Co., Ltd. Benzenesulfonamide derivative and process for preparing thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW287160B (enExample) * 1992-12-10 1996-10-01 Hoffmann La Roche

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510526A1 (de) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide
EP0526708A1 (de) * 1991-06-13 1993-02-10 F. Hoffmann-La Roche Ag Sulfonamide, ihre Herstellung und Verwendung als Heilmittel und Zwischenprodukte
EP0633259A1 (de) * 1993-06-28 1995-01-11 F. Hoffmann-La Roche Ag Neue Sulfonylaminopyrimidine, ihre Herstellung und Verwendung als Heilmittel
EP0658548A1 (en) * 1993-12-17 1995-06-21 Tanabe Seiyaku Co., Ltd. Benzenesulfonamide derivative and process for preparing thereof

Also Published As

Publication number Publication date
HU228619B1 (en) 2013-04-29
NO972538D0 (no) 1997-06-04
BR9510104A (pt) 1997-11-25
DE69531457D1 (en) 2003-09-11
CZ287916B6 (cs) 2001-03-14
IL116385A (en) 2000-07-16
KR100445085B1 (ko) 2004-10-14
FI972628A0 (fi) 1997-06-18
FI972628L (fi) 1997-06-18
NZ297797A (en) 1999-10-28
HK1001973A1 (en) 1998-07-24
FI120397B (fi) 2009-10-15
CY2495B1 (en) 2005-09-02
SA95160421B1 (ar) 2006-05-01
CA2208018A1 (en) 1996-06-27
ATE246681T1 (de) 2003-08-15
TW313568B (enExample) 1997-08-21
MA23744A1 (fr) 1996-07-01
IL116385A0 (en) 1996-03-31
MX9704587A (es) 1998-07-31
DK0799209T3 (da) 2003-11-24
DE69531457T2 (de) 2004-06-24
AU701767B2 (en) 1999-02-04
ES2203649T3 (es) 2004-04-16
AU4304196A (en) 1996-07-10
NO316645B1 (no) 2004-03-22
HUT77884A (hu) 1998-09-28
MY131126A (en) 2007-07-31
CZ187497A3 (en) 1997-10-15
PT799209E (pt) 2003-12-31
JP2989014B2 (ja) 1999-12-13
US6004965A (en) 1999-12-21
EP0799209B1 (en) 2003-08-06
NO972538L (no) 1997-06-04
EP0799209A1 (en) 1997-10-08
CN1170407A (zh) 1998-01-14
WO1996019459A1 (en) 1996-06-27
JPH10509182A (ja) 1998-09-08
CA2208018C (en) 2007-03-27

Similar Documents

Publication Publication Date Title
CN1098254C (zh) 新的磺酰胺
FI112944B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten sulfonyyliaminopyrimidiinijohdannaisten valmistamiseksi
JP3983477B2 (ja) エンドセリン受容体アンタゴニストとしての４−（ヘテロシクリルスルホンアミド）−５−メトキシ−６−（２−メトキシフェノキシ）−２−フェニル−又はピリジルピリミジン類
JP5575799B2 (ja) ７−フェノキシクロマンカルボン酸誘導体
JP2004517855A (ja) 新規なスルファミド類
RU2162084C2 (ru) Сульфонамиды и фармацевтический препарат
JP2004509874A (ja) 新規なアリールアルカン−スルフォンアミド類
JP2723496B2 (ja) 新規なスルホニルアミノピリミジン類
CN103459380B (zh) 苯基吡啶衍生物及含有该衍生物的医药
CN101056872A (zh) 用于治疗心血管疾病作为内皮素受体拮抗剂的磺酰二胺
RU2151767C1 (ru) Сульфонамиды и фармацевтическая композиция
PL185692B1 (pl) Nowe sulfonamidy, sposób ich wytwarzania oraz zawierające je preparaty farmaceutyczne
JPH08311043A (ja) スルホンアミド誘導体
CN1064965C (zh) 新的磺酰胺类化合物及其作为药物的用途
MXPA97004587A (es) Sulfonamidas novedosas
HK1001973B (en) Sulfonamides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20030108

EXPY Termination of patent right or utility model